Introduction
The number of patients with HIV/TB alliance has increased recently. There were 1055 TB/HIV cases registered in European Union (6% out of 17 650 TB cases tested for HIV) in 2010, among them 71 in Latvia (9.5% out of all TB cases in 2010, in comparison with 0.5% in 2000). The treatment for TB/HIV cases is provided in Latvia according to WHO recommendations, including DOTS strategy. However the TB treatment results for HIV positive cases are concerning due to increasing resistance to HIV/AIDS drugs and to TB drugs.
Methods
The treatment results for 7761 new smear and/or culture positive pulmonary TB cases were analyzed, 234 among them were HIV positive. In HIV/AIDS naive patients in general the resistance is found in 5.3% of cases. In treated patients the resistance to different groups of drugs is detected in 41% of cases: to all -3%, to NRTI -14%, to NRTI+NNRTI -9%, to NRTII+PL -6%, to NNRTI -6%, to NNRTI+PI -1%, to PI -2%. Multidrug resistance (MDR) was diagnosed in 14% of TB cases. Molecular biological, immunofluorescence, bacteriological and bacterioscopic methods were used for detection of initiating agents 
Results
The treatment success for HIV positive cases was lower in both periods (60-61%) in comparison with HIV negative cases (78-76%). The level of MDR TB cases among HIV positive patients was higher (15%) than in HIV negative patients (8%) 
Conclusions
The resistance to HIV/AIDS drugs is a factor influencing the TB treatment results.
